Table 1 Participant demographic, clinical and BoNT-A injection characteristics (N = 9)
Age | Gender | Diagnosis | Meas. side | Months post stroke/SCI | AIS (SCI) | BoNT-A injection | BoNT-A brand | BoNT-A dose per muscle (units) |
|---|---|---|---|---|---|---|---|---|
54 | M | Stroke (Ischaemic) | R | 12 | 4th | Dysport | GM (300); GL (300) | |
58 | M | Stroke (Ischaemic) | L | 69 | 5th | Allergan | SOL (50); GM (50) GL (50) | |
49 | M | Stroke (Hemorrhagic) | L | 64 | 1st | Dysport | SOL (400); GM (200) GL (200) | |
67 | M | SCI (C5–C7) | L | 30 | D | 8th | Dysport | SOL (300) |
62 | F | SCI (T7–T12) | L | 54 | B | 13th | Dysport | SOL (400); GM (200) GL (200); TP (200) |
29 | M | SCI (T7–T12) | R | 25 | A | 4th | Dysport | SOL (200); GM (200) GL (100) |
51 | M | SCI (T7–T12) | R | 183 | C | 3rd | Dysport | SOL (300); GM (200) GL (200) |
59 | M | SCI (L1) | L | 144 | C | 7th | Dysport | SOL (150); GM (160) GL (160) |
61 | F | Cauda equina syndrome (L4–L5) | R | 17 | 1st | Dysport | SOL (300); GM (200) GL (200); TP (300) |